ORION OYJ |
Market Closed -
Other stock markets
|
After market 02:52:29 pm | |||
| 35.39 EUR | +6.92% |
|
35.46 | +0.20% |
| Sales 2024 * | 1.37B 1.47B | Sales 2025 * | 1.45B 1.55B | Capitalization | 4.67B 5B |
|---|---|---|---|---|---|
| Net income 2024 * | 237M 254M | Net income 2025 * | 249M 267M | EV / Sales 2024 * | 3.4 x |
| Net cash position 2024 * | 7.88M 8.45M | Net Debt 2025 * | 3.07M 3.29M | EV / Sales 2025 * | 3.23 x |
| P/E ratio 2024 * |
19.6
x | P/E ratio 2025 * |
18.7
x | Employees | 3,632 |
| Yield 2024 * |
5.03% | Yield 2025 * |
5.17% | Free-Float | 88.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | +4.29% | ||
| 1 week | +3.28% | ||
| Current month | -3.59% | ||
| 1 month | -2.46% | ||
| 3 months | -23.87% | ||
| 6 months | -8.26% | ||
| Current year | -15.13% |
1 week
31.86
34.17
1 month
31.8634.86
Current year
31.8645.29
1 year
31.8646.97
3 years
31.8655.16
5 years
28.1955.16
10 years
21.4458.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Director of Finance/CFO | 63 | 00-12-31 | |
| Chief Operating Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 1,331 M€ | +6.01% | ||
| 2.87% | 460 M€ | +0.87% | ||
| 0.35% | 1,120 M€ | +0.38% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 35.39 | +6.92% | 804 108 |
| 24-04-24 | 33.1 | -0.06% | 312,458 |
| 24-04-23 | 33.12 | +0.36% | 201,846 |
| 24-04-22 | 33 | +1.85% | 234,335 |
| 24-04-19 | 32.4 | +0.40% | 164,600 |
Delayed Quote Nasdaq Helsinki, April 25, 2024 at 05:01 am EDT
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
05:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
33.1
EUR
Average target price
39.2
EUR
Spread / Average Target
+18.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.13% | 4.99B | |
| +25.61% | 660B | |
| +23.79% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.58% | 219B | |
| -9.82% | 196B | |
| +6.80% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- ORNBV Stock
